ResultsIQ › Latest results › Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies Limited Q2 FY27 earnings call summary
NSE: SMT · BSE: 545001
Earnings call of 5 Nov 2026, summarised by AI from the filing.
Structural heart grew about 40% in Q2 and ROW 37% in H1, now the largest region at 40% of revenue.
Key takeaways
- Growth mix Structural heart grew about 40% in Q2 and ROW 37% in H1, now the largest region at 40% of revenue.
- Operating leverage Employee cost fell to 27.1% of revenue from 28.8% and other expenses to 29.7% from 31.5%, lifting EBITDA margin.
- Gross margin H1 gross margin 74.3% vs 76%, down about 170 bps, about 150 bps from faster-growing lower-margin traded products.
Sahajanand Medical Technologies Limited Q2 FY27 results
As filed: Revenue ₹373 cr, EBITDA ₹65.6 cr, PAT ₹26.5 cr, EBITDA margin 17.6%.
Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹373 cr). Scored once a year-earlier consolidated quarter exists.
Sahajanand Medical Technologies Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.